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Background: Male sex is associated with better lung function and survival in people 
with cystic fibrosis but it is unclear whether the survival benefit is solely due to the 
sex-effect on lung function. 
 
Methods: Longitudinal registry study of the UK cystic fibrosis registry between 1996 
and 2015. We apply recently developed methodology for the joint analysis of repeated 
measurements and time-to-event outcomes to assess how much of the sex effect on 
survival is explained by the sex effect on lung function. These methods allow 
examination of association between %FEV1 (overall level and rate of decline) and 
covariates such as sex and genotype, and survival, in the same modelling framework. 
A probit model is used for the probability of surviving one more year, so a positive 
coefficient reflects an increase in survival probability. 
 
Results: The dataset includes 81,129 lung function measurements of %FEV1 on 
9,741 patients seen between 1996 and 2015 and captures 1,543 deaths. Males 
compared to females experienced a more gradual decline in %FEV1 (difference 0.11 
per year 95%CI 0.08 to 0.14). After adjusting for confounders, both overall level of 
%FEV1 and %FEV1 rate of change are associated with the concurrent hazard for 
death. There was evidence of a male survival advantage (probit coefficient 0.15 95% 
CI 0.10, 0.19) which changed little after adjustment for %FEV1 using conventional 
approaches but was  attenuated by 37% on adjustment for %FEV1 level and slope in 
the joint model (0.09 95% CI 0.06, 0.12).  
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Conclusions: About 37% of the association of sex on survival in cystic fibrosis is 
mediated through lung function.  
 




In people with cystic fibrosis it remains controversial whether and how sex influences 
survival chances, with many studies showing worse survival in females, even after 
adjustment for measures of lung function. 
Previous analyses exploring the sex gap in cystic fibrosis may not have sufficiently 
adjusted for lung function, since standard statistical approaches are limited in the 
presence of significant error in the measurement of time-varying covariates such as 
%FEV1, the standard measure of lung function in cystic fibrosis We apply recently 
developed methodology for the joint analysis of repeated measurements and time-to-
event outcomes to overcome this issue, and show that about forty percent of the 






Male sex has been identified as a positive prognostic factor in cystic fibrosis (1–3). 
The effect of sex on morbidity and mortality in cystic fibrosis, with males having 
better outcomes, has been a common finding in large epidemiological studies, first 
suggested in US centres (4), and then confirmed in US population level registry 
studies (5,6). There have been similar findings in the UK (7), with Barr et al in the 
UK (8) suggesting that despite overall improved survival in the 21st century, females 
continue to be more likely to die below the median age of death compared to males, a 
pattern that has persisted since the 1960s. There has been recent debate about the sex 
gap, suggesting that this may be narrowing over time as a result of improving 
treatment (9,10). In terms of use of health services in cystic fibrosis, a large study in 
Canada further demonstrated decreased risk of hospitalisation in males (11). Our 
previous study of the UK cystic fibrosis Registry shows that the sex effect on cystic 
fibrosis outcomes is clearly apparent in the UK cystic fibrosis population (12) and this 
is also shown in a recent survival analysis using UK data (13,14) . The cause of the 
sex gap in survival remains unclear. Lung function, as measured by the per cent 
predicted forced expiratory volume in 1 s (%FEV1) is commonly used as a measure of 
disease severity in cystic fibrosis, and has been shown to be related to survival. One 
explanation for the sex gap in cystic fibrosis survival is that this is explained by worse 
lung function in females. For instance, some studies suggest that females may be 
more likely to become colonized with P. aeruginosa leading to lung damage at an 
earlier age (15), and this may be related to the effect of oestrogen (16). A recent 
review of the sex effect in cystic fibrosis has suggested that the finding of lower 
female survival is evident in most studies, and that evidence to suggest closure of the 
sex gap in recent cohorts is less convincing than the data supporting its continued 
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existence. The review does suggest that in cohorts of adults with late diagnosis, and 
conditional on survival to age 40 years, the  sex gap appears to narrow or even be 
reversed(3).  
 
In this study we aim to quantify how aspects of an individual cystic fibrosis patient’s 
longitudinal profile of lung function is related to their survival prognosis; and to 
decompose the impact of sex on these joint outcomes. Joint modelling approaches are 
potentially of great utility in the context of studying outcomes in cystic fibrosis 
patients (17). Survival is of central interest and analyses often seek to adjust for lung 
function as a time-varying covariate, which we know is measured imprecisely with 
clinically significant measurement error. Furthermore, the dynamics of lung function 
decline are also of interest, but there is potentially informative drop-out due to the 
direct link between lung function and survival prognosis.  Together, these properties 
of cystic fibrosis data (measurement error and dropout) mean that separate analysis of 
repeated measurement and survival outcomes is potentially inefficient, because it does 
not exploit the dependence between the repeated measurement process and the hazard 
for survival, and leads to biased estimation of the association between the two, 
because it ignores measurement error.(18)  Joint modelling of lung function and 
survival offers an approach to address all of these issues.  
 
Joint modelling has been applied to cystic fibrosis data in a few previous studies. The 
first of these was a centre-level study by Schluchter and colleagues that modelled 
longitudinal FEV1 and survival simultaneously for a cohort of delF508 homozygous 
patients, but this study did not explore the sex effect (17).  Subsequently cystic 
fibrosis data has been used to develop methods for joint modelling, including an 
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approach that we previously developed (19). In this study we apply this novel 
approach for the joint modelling of lung function and survival, and contrast this to 
commonly used approaches to adjusting for time-varying covariates in survival 
analyses. We use the joint model to test the hypothesis that the survival advantage for 




We undertook a longitudinal retrospective cohort study of individuals in the UK 
cystic fibrosis registry, which records longitudinal health data on all people with 
cystic fibrosis in England, Wales, Scotland and Northern Ireland. All UK cystic 
fibrosis centres and clinics routinely collect data in a standardised fashion. When 
patients with cystic fibrosis attend a new centre in the UK, they or their parent’s 
consent to information on their health and treatment being collected and stored in the 
cystic fibrosis Registry (20). In the UK cystic fibrosis patients are seen in the 
outpatient clinic for a comprehensive annual review, including evaluation of clinical 
status and pulmonary function. The UK cystic fibrosis Registry is supported and 
coordinated by the UK Cystic fibrosis Trust. In the UK, the Registry is estimated to 
capture almost all of the cystic fibrosis population; any consenting patients attending 
NHS clinics will have annual data routinely collected into the database, 89% of whom 
have a ‘complete’ dataset capturing key clinical parameters over time. The registry is 
carefully managed and curated to a high level of data quality, and is therefore ideally 
suited to the study of cystic fibrosis outcomes (20). 
 
Primary outcome and covariates 
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Our directed acyclic graph which informed the analysis, identifying variables in the 
minimally sufficient set of adjustments, is shown in figure 1. The primary outcomes 
were %FEV1, as per other studies that have explored the cystic fibrosis sex gap in 
outcomes (5), and survival.  Pulmonary function tests were measured annually at the 
review visit, and performed according to international recommendations, measuring 
forced expiratory volume in one second, expressed as a percentage of predicted values 
for sex, age, height and ethnicity using the GLI reference equations (21). We 
restricted the analysis to white patients under the age of 40 at last follow-up, with at 
least one lung function measurement between the start of 1996 and end of 2015. We 
chose to apply an upper age limit to the analysis since the female sex gap has been 
shown to be present up to this point; and we have previously shown that random 
intercept and slope models make unrealistic assumptions when applied over long 
periods (22). 97% of people with cystic fibrosis in the UK are white. Non-white 
patients tend to have worse outcomes, but the numbers are small in the UK, restricting 
power to demonstrate subgroup effects (12).		
 
The primary exposure of interest was male sex. The time metameter was patient age 
at clinic visit at which the %FEV1 measure was taken. Other covariates in the 
analysis were genotype coded as the number of delta F508 alleles (0, 1 or 2) and	
dichotomised into 2 F508 alleles versus 0 or 1 alleles or not typed,  and birth year 
which was treated as a continuous covariate and centred at the mean value 





Full details of the joint modelling approach are provided in the supplementary 
eAppendix 1. We applied the method developed by Barrett et al, which allows exact 
likelihood inference for a wide range of random-effect specifications, and the code for 
fitting this model is available via the link ( 
https://github.com/Jessbarrett/CysticFibrosisJM). Repeated %FEV1 measures on 
individuals are correlated, and this must be accommodated to obtain valid inferences. 
Furthermore, lung function is related to survival.  Thus repeated measurements of 
%FEV1 and survival were modelled jointly using shared random effects to account for 
the interdependence of the two processes (19). The sub-model for %FEV1 adjusted for 
the patient’s age at measurement, birth year, sex and number of F508 alleles. 
Exploratory plots of the data are shown in eAppendix2. Informed by these, we 
approximated time-trends with a quadratic time function,  to accommodate non-linear 
change over time (22). Interactions were included between the linear time variables in 
age and birth year and all other covariates. Birth year was included to account for 
cohort effects and a survivor effect arising from left truncation of the data at the start 
of follow-up. The intercept (level of %FEV1 at age five) and age effect (annual linear 
change in %FEV1) were treated as normally distributed, correlated random effects to 
allow for individual intercepts and slopes. The random effects in the longitudinal 
model capture other sources of unmeasured heterogeneity not captured by the fixed 
effects.   
 
Subjects entered the cohort at different ages, so that patients contributed person years 
to the analysis only at ages corresponding to their actual ages during the study period.  
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The probability of surviving one year was modelled using a probit link function. The 
survival sub-model was adjusted for age halfway through the year, birth year, sex, and 
F508 alleles (dichotomised as previously). In addition, the survival sub-model 
depended on a patient’s %FEV1 value halfway through the year and their %FEV1 rate 
of change, as estimated by the longitudinal %FEV1 model including the random 
effects. The time-to-event sub-model is specified on a discrete  time scale modelling 
the conditional probability of surviving one year given that you have survived to the 
start of the year,	whereby a positive coefficient means that an increase in the predictor 
leads to an increase in the predicted probability of survival. The effect of %FEV1 
level and %FEV1 rate of change on survival were also expressed as hazard ratios (see 
the statistical eAppendix1 for details of estimating hazard ratios from our survival 
model). Note that for the hazard ratios the direction of effect is reversed, i.e. a hazard 
ratio >1 means that an increase in the predictor gives a decreased probability of 
survival.  
 
We assess whether there is a direct association between sex and survival according to 
the directed acyclic graph in figure 1, after accounting for lung function. Our 
coefficient of interest in the joint model is the sex effect in the survival sub-model, 
after adjustment for %FEV1 rate of change and overall level of %FEV1 (for full 
algebraic details see eAppendix1). In order to demonstrate the utility of using a joint 
modelling approach to test our hypothesis we assessed how the association between 
sex and survival changed depending on the modelling approach. Once we fitted the 
joint model to the data we compared the association between sex and survival to that 
in a standard probit survival model, first without any adjustment for %FEV1, and then 
with %FEV1 added as a baseline time-invariant covariate (i.e. %FEV1 at first visit), 
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and finally as a time-varying covariate. We estimated all model parameters by 
maximum likelihood and used generalized likelihood ratio statistics to compare 
nested models, and Wald statistics to test hypotheses about model parameters.We 
plotted residual diagnostics for the longitudinal and survival sub-models, and an 
empirical variogram to check our model fit. 
 
Ethics 
NHS research ethics approval (Huntingdon Research Ethics Committee 07/Q0104/2) 
has been granted for the collection of data into the UK database. The cystic fibrosis 






The dataset contained 81,129 lung function measures on 9,741 patients between 1996 
and 2015 in the UK, and captured 1,543 deaths. The median number of %FEV1 
measures per person was 8 (range 1 – 25). 87% of individuals had 3 or more follow 
up measures with a total of 96,598 person-years of follow up. The baseline 
characteristics of the population, stratified by sex are shown in Table 1.  
 
Associations of covariates with lung function trajectory 
 
We explored the effect of covariates on %FEV1. Results from the %FEV1 sub-model 
are shown in Table 2. Random effect parameter estimates are reported in 
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Supplementary Table 1.  There was a borderline difference between males and 
females in the level of %FEV1 at age five with difference in intercept of 0.90  (95% 
CI 0.01 to 1.80). %FEV1 initially declined at a rate of -1.52 (95%CI -1.58 to -1.45) 
percentage points per year for females. Males experienced a more gradual decline in 
%FEV1 (difference 0.11 per year 95%CI 0.08 to 0.14). Lung function declined at a 
faster rate for patients with 2 F508 alleles compared to those with 0 or 1 F508 alleles 
(-0.35  percentage points per year 95% CI -0.45 to -0.25).  
 
Associations of covariates with survival 
 
Table 3 shows the results from the survival models. The joint model (column 1) 
shows that higher overall levels of %FEV1 and a more gradual %FEV1 decline were 
associated with improved survival. Figure 2 provides a visual illustration of the 
relationship between lung function and survival for individuals selected from the 
population with different %FEV1 trajectories (different random effects). For example, 
for 20-year old males born in 1980 with 2 F508 alleles and population-average 
%FEV1 level and %FEV1 decline, a 10-unit lower level of %FEV1 is associated with 
an increase in the concurrent hazard of death (HR 2.26 CI 2.13 to 2.41). Furthermore 
those with a 1-unit per year decline compared to no decline in %FEV1 have over a 
threefold higher hazard of death for every year that passes (HR 3.67 CI 3.31 to 4.07). 
 
Figure 3 visualizes the association of sex with lung function and survival in the joint 
model. Males have a more favourable %FEV1 and survival trajectory. Note that the 
estimated sex effects in figure 3 are population-averaged effects, that is, they describe 
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average values of %FEV1 for sub-populations of individuals sharing the same 
explanatory characteristics, rather than for any one individual. 
 
Association between female sex and survival adjusted for lung function 
  
In table 3 we compare the results of four possible survival models that adjust for 
%FEV1 in various ways. Contrasting the association of sex with survival across these 
models, in all three of the standard survival models there is a strong  association 
between sex and survival in models without adjustment for %FEV1; and with 
adjustment for % FEV1 either as a baseline or as a  time-varying covariate (effect 
sizes  0.15, 0.13, 0.14,  i.e. males have better survival than females). By contrast we 
observe less  association between sex and survival after adjusting for %FEV1 (level 
and rate of decline) in the joint model, with an effect size attenuated by 37% to 0.09  
(95%CI 0.06, 0.12).  Table 3 also shows that the genotype effect is reversed once we 
adjust for longitudinal lung function in the joint model. . Residual diagnostics did not 




We apply a novel joint modelling approach, for the first time, to show that about forty 
percent of theassociation of female sex on survival in cystic fibrosis is  explained by 
the effect of sex on lung function. Both an increased rate of decline in lung function, 
and a decreased overall level of lung function are associated with an increased risk of 
death. A strength of this analysis is the use of a joint modelling approach which leads 
to more robust estimation of both survival estimates and the rate of lung function 
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decline. Our joint modelling approach allows exploration of how aspects of an 
individual cystic fibrosis patient’s longitudinal profile of %FEV1 are related to their 
survival prognosis. A key advantage of the joint model is that it estimates the 
relationship between characteristics of the “true” error free underlying %FEV1 trace 
and survival. Our analysis here suggests that measurement error contributes to the 
finding that conventional approaches to adjusting for %FEV1 level in survival 
analysis suggest a significant sex association, but this is attenuated once error free 
%FEV1 is taken into account in the joint model.   
 
Many studies have explored survival in cystic fibrosis (1,2,13), and notable among 
these are the large studies from North America that have used Cox regression to 
estimate the effect of various covariates on survival chances in registry populations 
(5,6,23). A large number of factors have been identified that may influence survival, 
with female sex identified most commonly as a risk factor. Other influences include 
poor respiratory function and risk factors for poor lung function such as P. aeruginosa 
infection status, homozygous delta F508 status or heterozygous non delta F508 status, 
non-white ethnicity, and low income. Many studies have investigated the impact of 
baseline time invariant factors on survival, including a recent study using UK data by 
Keogh and colleagues which showed a clear sex effect, with worse survival for 
female patients (13). Where studies have investigated time varying predictors such as 
lung function, these have been included in survival models as current values. To our 
knowledge our study is one of the first to quantify the association of rate of lung 
function decline with survival using a joint modelling approach. Another recent study 
by Keogh et al used landmarking to predict survival in the UK population, and used a 
two stage approach whereby fitted values from a longitudinal mixed effects model for 
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%FEV1 were used to estimate current values of %FEV1 for inclusion in the second 
stage landmarking analysis (14). The study found that current %FEV1 was the 
strongest predictor of survival. Like in our joint model, this two-stage landmarking 
approach could also be used to estimate the association of the recent rate of decline of 
%FEV1 with survival .  
 
There is a large literature on lung function decline in people with cystic fibrosis. 
Konstan et al have undertaken the largest studies to date of %FEV1 in both paediatric 
and adult cohorts (24–26), using a mixed-effects regression approaches, to show that 
higher baseline %FEV1, P. aeruginosa colonisation, female sex, and poor nutritional 
status were amongst the factors associated with a greater decline in lung function in 
people with cystic fibrosis(24). Our analysis contributes to this literature by explicitly 
quantifying how longitudinal changes in lung function are related to survival. Both an 
increased rate of decline in lung function, and a decreased overall level of lung 
function are associated with an increased risk of death in people with cystic fibrosis.  
 
Large national cystic fibrosis patient registry data in different countries have shown 
that survival for cystic fibrosis females was less than that for matched cystic fibrosis 
males, identifying a ‘sex gap’. The aetiology of this is poorly understood, with 
increased mortality in females seen even after correcting for lung function, suggesting 
the explanation is likely to be multifactorial. Our analysis adds to this literature, 
suggesting that around forty percent of the effect of sex on survival is explained by 
the impact of sex on lung function decline, which in turn influences survival. There 
are known effects of sex on lung function, and acquisition of P. aeruginosa which we 
have previously identified in this dataset (12). Alternative biological reasons have 
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been suggested, including the impact of oestrogen and increased occurrence of cystic 
fibrosis related diabetes (3,8). Social explanations have also been suggested. These 
may relate to gender roles, such as a possible propensity to less exercise in childhood 
in girls, and an increased tolerance of poor nutritional status in adolescent girls with 
cystic fibrosis, fuelled by the societal pressure to appear thin(27). 
 
Our analysis suggests that the sex gap may be partly explained by worse lung function 
in females. We suggest that standard approaches for adjusting for lung function in 
survival analysis may lead to insufficient adjustment, which may explain the 
difference between our results, and other large epidemiological studies of cystic 
fibrosis. Since lung function is measured with significant error, the associations with 
other covariates in the analysis may be confounded by residual effects of lung 
function. In our joint model, which more precisely adjusts for underlying lung 
function, differences in lung function  explain about forty percent of the sex 
difference in mortality. For instance, one of the largest studies to explore the gender 
gap in cystic fibrosis was Rosenfeld and colleagues’ analysis of US registry data (5), 
which showed a significant association of sex on survival and lung function. The 
authors show that pulmonary function was the only risk factor that explained a portion 
of the observed gender-related difference in survival. Among the subjects 1-20 years 
of age, females had a hazard ratio of 1.7  in the unadjustedCox regression analysis, 
but this was attenuated to 1.5  whilst adjusting for %FEV1 as a time varying covariate 
The authors suggest that differences in pulmonary function did appear to explain a 
small portion of the excess female mortality, but no other factor further accounted for 
the gender gap. A more recent large study of US registry data identified a survival 
advantage for males compared with females, with a 19% (CI, 13% to 24%) lower 
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adjusted risk for death in males as compared to females (28), and the authors further 
highlight that the reasons for this are not well-understood. However, this analysis did 
not adjust for lung function at a time-varying covariate, but focused on adjustment for 
baseline factors at the time of diagnosis, which can be used by clinicians at diagnosis 
to inform discussions about patient prognosis.  	
 
To our knowledge this is the first study to explore the sex effect in cystic fibrosis 
using joint modelling approaches, though previous studies have used cystic fibrosis 
data to develop joint modelling methods (19).  Key strengths of this study include the 
population-wide coverage of the UK cystic fibrosis registry and the high quality of the 
data (20). Although we have not presented our analysis as a formal mediation 
analysis, the steps we have undertaken map onto the Baron and Kenny steps for 
mediation analysis, subject to a number of assumptions (see eAppendix2). Newer 
methods for mediation analysis based on the counterfactual framework, and software 
to implement them are developing rapidly, and further work is warranted to 
understand how joint models can be used within the potential outcomes framework. 
Such approaches could be usefully applied to range of mediation questions in cystic 
fibrosis epidemiology. For example, whilst not the main focus of our analysis here, 
the reversal of the genotype effect in our joint model suggests that heterozygotes for 
del508, compared to those with one or no del508 alleles, have better survival after 
adjustment for lung function. Further analyses could explore decomposing the sex 
effect on survival through a potential effect of sex on P. aeruginosa acquisition which 
is known to impact lung function decline.  
There are a number of limitations: First, it relies on retrospective, routinely collected 
data.  Secondly, our joint modelling approach assumes that %FEV1 measurements are 
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independent of survival given an individual’s random effect values, which may not be 
appropriate. Thirdly, we did not explore the full range of mediating pathways through 
which sex may impact on survival. Our main hypothesis related to the sex term in the 
survival sub-model, and we did not seek to adjust for other potential downstream 
mediators of the association between sex and survival in the survival sub-model, such 
as cystic fibrosis related diabetes and infection status indicators, instead adjusting for 
slope and overall level of lung function as captured in our longitudinal sub-model. 
Whilst the random effects included in the longitudinal component of our joint model 
capture residual underlying baseline heterogeneity they are unlikely to adequately 
capture time-varying effects such as infections. The impact of infection on survival, 
however, is likely to be largely mediated through impacts on lung function. A recent 
study has illustrated how left truncation can lead to biased estimates in the context of 
joint models (29). We aimed to limit the impact of left truncation by including birth 
year as a covariate in the longitudinal and survival sub-models. The effect of birth 
year here is driven by both cohort effects and left truncation. Another limitation of our 
study is that is debatable as to how transplanted individuals should be handled in a 
joint model (14).For the purposes of this analysis we included post-transplant FEV1 
measures and deaths, but further work is needed to understand how best to take 
account of transplantation and post transplant survival in the context of a joint 
modelling analysis. 
 
In summary we have applied the Barrett et al (19)  approach to joint modelling in 
cystic fibrosis to address the question of how the sex effect on survival is explained 
by lung function. Our analysis suggests that if the lung function gap between males 
and females can be narrowed, this should also narrow the survival gap. Our analysis 
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approach can be applied to similar aetiological questions in longitudinal cystic 
fibrosis registry data, and can be used to more accurately adjust for time-varying 
covariates measured with error, such as lung function, in survival analyses in cystic 
fibrosis and other conditions. 
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Table 1: Characteristics of study population by sex: UK cystic fibrosis registry  
 
  Female Male All 
N (%) 4605 (47) 5136 (53) 9741 
Observation (%) 37849 (47) 43280 (53) 81129 
Observations per patient* 8.2 (4.7) 8.4 (4.8) 8.3 (4.8) 
Deaths (%) 813 (53) 730 (47) 1543 
    
Genotype    
No. delta 508: 2 (%) 2361 (51) 2752 (54) 5113 (53) 
No. delta 508: 1 (%) 1718 (37) 1782 (354) 3500 (36.) 
No. delta 508: 0 (%) 327 (7.1) 354 (6.9) 681 (7.0) 
Missing 199 (4.3) 248 (4.8) 447 (4.6) 
    
Birth cohort (%)    
<1960 3 (0.1) 4 (0.1) 7 (0.1) 
1960-1964 68 (1.5) 115 (2.2) 183 (1.9) 
1965-1969 141 (3.1) 199 (3.9) 340 (3.5) 
1970-1974 257 (5.6) 335 (6.5) 592 (6.1) 
1975-1979 365 (7.9) 473 (9.2) 838 (8.6) 
1980-1984 587 (13) 686 (13) 1273 (13) 
1985-1989 668 (15.) 772 (15) 1440 (15) 
1990-1994 722 (16) 749 (15) 1471 (15) 
>1995 1794 (39) 1803 (35) 3597 (37) 
    
Age at entry* 19.2 (9.0) 20.0 (9.4) 19.6 (9.2) 
Age at diagnosis* 
(Missing, n=118) 
3.0 (6.5) 3.0 (6.8) 3.0 (6.7) 
 
*Reported as mean (SD) 
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Table 2 Joint model results for the %FEV1 sub-model. Fixed effects estimates of 
association of covariates on forced expiratory volume in 1 s as a percentage of 
predicted (%FEV1). 
 Estimate (95% CI) 
Intercept at age 5 years 87.98 (87.32, 88.65) 
Age* -1.52 (-1.58, -1.45) 
Age squared 0.01 (0.01, 0.01) 
Birth year 0.22 (0.15, 0.29) 
Male 0.90 (0.01, 1.80) 
F508 alleles: 2 vs 0, 1 or not typed -0.08 (-1.17, 1.01) 
Age x male 0.11 (0.08, 0.14) 
Age x F508 alleles: 2 vs 0, 1 or not typed -0.35 (-0.45, -0.25) 
Birth year x male 0.06 (-0.03, 0.15) 
Birth year x F508 alleles: 2 vs 0, 1 or not typed -0.004 (-0.07, 0.06) 
*Age term corresponds to %FEV1 slope. The age x male term represents the age by sex interaction i.e. 
the difference in slope for males compared to females  
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Table 3. Parameter estimates (95% CI) from the probit survival models. A positive coefficient means that an increase in the predictor 
leads to an increase in the predicted probability of survival.  
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Figure 1. Directed acyclic graph for the effect of sex on key outcomes in cystic 
fibrosis. We aim to use a joint model to test the hypothesis that there is a direct 





Figure 2. Estimated longitudinal trajectories and survival curves for 20-year-old 






Figure 3. Estimated longitudinal trajectories and survival curves for males and 
females age 20, born in 1980 with 2 F508 alleles. 
 
Effect of sex on forced expiratory volume in 1 s as a percentage of predicted (%FEV1) 
and survival in the final joint model.  
 
 
